$ 27.33
Key Takeaways
Risk factor
High price volatility
Profitability factor
Greatly overvalued vs peers
About
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is 'expensive' on EV/EBITDA, trading at neutra
Target Price
The average target price of STAA is 25 and suggests 8% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to decrea
